GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Median PS Value

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Median PS Value

: $1.53 (As of Today)
View and export this data going back to 2007. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sonoma Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.218. Sonoma Pharmaceuticals's 10-Year median PS Ratio is 0.6898. Therefore, the Median PS Value for today is $1.53.

As of today (2024-04-19), Sonoma Pharmaceuticals's share price is $0.15. Sonoma Pharmaceuticals's Median PS Value is $1.53. Therefore, Sonoma Pharmaceuticals's Price to Median PS Value for today is 0.10.

The historical rank and industry rank for Sonoma Pharmaceuticals's Median PS Value or its related term are showing as below:

SNOA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1   Med: 0.58   Max: 0.98
Current: 0.1

During the past 13 years, the highest Price to Median PS Value of Sonoma Pharmaceuticals was 0.98. The lowest was 0.10. And the median was 0.58.

SNOA's Price-to-Median-PS-Value is ranked better than
98.2% of 501 companies
in the Drug Manufacturers industry
Industry Median: 0.77 vs SNOA: 0.10

Sonoma Pharmaceuticals Median PS Value Historical Data

The historical data trend for Sonoma Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.25 15.46 9.50 4.70 3.16

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.32 3.16 2.57 2.08 1.53

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals Price-to-Median-PS-Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Price-to-Median-PS-Value falls into.



Sonoma Pharmaceuticals Median PS Value Calculation

Sonoma Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=2.218*0.6898
=1.53

10-Year Median PS Ratio is 0.6898.
Sonoma Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.218.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonoma Pharmaceuticals  (NAS:SNOA) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Sonoma Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.15/1.53
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sonoma Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Headlines

From GuruFocus